Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall
Merck and Moderna reported that their combined mRNA cancer vaccine and immunotherapy reduced melanoma death or recurrence risk by 42% in a Phase 3 trial. Moderna shares fell 17% despite prior gains, while Merck shares dropped 1.8%. The vaccine, tested with Keytruda, showed significant efficacy, with 82.2% of patients cancer-free after two years. The companies plan to seek US approval and launch in 2027.
How this was made
The 30-second read
Why it matters
The unexpected data leak triggered immediate price declines for both companies, highlighting market sensitivity to oncology trial outcomes.
Market read
First report of pivotal trial data creates short‑term trading opportunities and informs longer‑term oncology pipeline valuations.
What to watch
Regulatory filing plans and 2027 launch timeline could support future upside.
Background
Phase 3 trial of Moderna's personalized mRNA vaccine combined with Merck's Keytruda showed a 42% cut in melanoma death/recurrence risk.
Ticker impact
Moderna shares fell ~17% after the Phase 3 melanoma vaccine data were leaked, indicating immediate price impact.
likely pressure as investors reassess valuation after the data release
The trial showed a 42% reduction in death/recurrence but the surprise leak caused a sharp sell‑off.
Merck stock closed down about 1.8% following the same trial data, reflecting a modest negative reaction.
moderate pressure as the market prices in the trial outcome
Even a small decline after a major trial indicates investors are cautious about future sales.
Market effects
The results could temper enthusiasm for melanoma immunotherapy combos across biotech.
US biotech sector may see slight pullback as investors await further data.
International investors in oncology pipelines may reassess exposure.
Counterpoint
Some analysts may view the 42% risk reduction as a long‑term win despite short‑term sell‑off.
Key entities
- CompanyModerna
Biotech firm developing mRNA therapeutics.
- CompanyMerck
Pharmaceutical giant behind Keytruda.
